Pacran®, a powder obtained from cranberries, and defence against bacterial pathogens in the lower urinary tract: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Following an application from Givaudan, submitted for authorisation of a healthclaim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the CompetentAuthority of Italy, the EFSA Panel on Nutrition, Novel Foods and Food Allergens(NDA) was asked to deliver an opinion on the scientific subst...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/174194 |
| Acceso en línea: | https://hdl.handle.net/11441/174194 https://doi.org/10.2903/j.efsa.2025.9319 |
| Access Level: | acceso abierto |
| Palabra clave: | Cranberry Health claim Urinary tract infection |
| Sumario: | Following an application from Givaudan, submitted for authorisation of a healthclaim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the CompetentAuthority of Italy, the EFSA Panel on Nutrition, Novel Foods and Food Allergens(NDA) was asked to deliver an opinion on the scientific substantiation of a healthclaim related to Pacran® and defence against bacterial pathogens in the lowerurinary tract. The Panel considers that the food Pacran®, a powder obtained fromcranberries, is sufficiently characterised. Defence against bacterial pathogens inthe lower urinary tract is a beneficial physiological effect. The applicant identi-fied two human intervention studies which investigated the effect of Pacran® onthe incidence of urinary tract infections (UTI) as being pertinent to the claim. Inweighing the evidence, the Panel took into account that one human interventionstudy showed a beneficial effect of Pacran® consumed daily at doses of 500 mg for6 months on the incidence of symptomatic, culture-confirmed UTI in women witha history of recurrent UTI, whereas such an effect was not consistently observedin another study under similar conditions. The Panel also took into account thatlimited evidence has been provided for a mechanism by which Pacran® could exertthe claimed effect. The Panel concludes that the evidence provided is insufficientto establish a cause and effect relationship between the consumption of Pacran®and the defence against bacterial pathogens in the lower urinary tract. |
|---|